NASDAQ:FATE

Fate Therapeutics (FATE) Stock Forecast, Price & News

$2.18

+0.08 (+3.81%)

(As of 09/28/2023 ET)

Compare

Today's Range: $2.03
▼
$2.19
50-Day Range: $2.02
▼
$4.46
52-Week Range: $1.99
▼
$23.96

Volume: 1.54 million shs
Average Volume: 3.27 million shs
Market Capitalization: $214.86 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.96

Fate Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.15 Rating Score
Upside/Downside: 494.6% Upside
$12.96 Price Target
Short Interest: Bearish
26.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.70
Upright™ Environmental Score
News Sentiment: 1.37
Based on 2 Articles This Week
Insider Trading: Selling Shares
$59,353 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.91) to ($2.13) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

195th out of 969 stocks

Biological Products, Except Diagnostic Industry

26th out of 161 stocks

4.1

Analyst's Opinion

Consensus Rating
Fate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.15, and is based on 5 buy ratings, 13 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.96, Fate Therapeutics has a forecasted upside of 494.6% from its current price of $2.18.
Amount of Analyst Coverage
Fate Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
26.17% of the float of Fate Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Fate Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Fate Therapeutics has recently decreased by 12.12%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Fate Therapeutics does not currently pay a dividend.
Dividend Growth
Fate Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Fate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Fate Therapeutics is -0.70.

3.5

News and Social Media Coverage

News Sentiment
Fate Therapeutics has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Fate Therapeutics this week, compared to 4 articles on an average week.
Search Interest
4 people have searched for FATE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
2 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,353.00 in company stock.
Percentage Held by Insiders
Only 5.04% of the stock of Fate Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Fate Therapeutics are expected to decrease in the coming year, from ($1.91) to ($2.13) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fate Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fate Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fate Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE Price History

30 days | 90 days | 365 days | Advanced Chart

FATE Stock News Headlines

September 7, 2023 | msn.com

Cantor Fitzgerald Reiterates Fate Therapeutics (FATE) Neutral Recommendation

August 31, 2023 | finance.yahoo.com

Fate Therapeutics to Present at Upcoming September Investor Conferences

September 29, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 17, 2023 | msn.com

Truist Securities Reiterates Fate Therapeutics (FATE) Hold Recommendation

August 16, 2023 | msn.com

Fate Therapeutics: Not Now, Maybe Never?

August 16, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Fate Therapeutics

August 11, 2023 | msn.com

Morgan Stanley Maintains Fate Therapeutics (FATE) Equal-Weight Recommendation

August 10, 2023 | msn.com

EF Hutton Reiterates Fate Therapeutics (FATE) Buy Recommendation

September 29, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 10, 2023 | msn.com

BMO Capital Maintains Fate Therapeutics (FATE) Market Perform Recommendation

August 9, 2023 | finance.yahoo.com

FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss

August 8, 2023 | finance.yahoo.com

Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates

August 8, 2023 | finance.yahoo.com

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

July 28, 2023 | finance.yahoo.com

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

July 22, 2023 | finance.yahoo.com

One Fate Therapeutics Insider Raised Stake By 83% In Previous Year

July 17, 2023 | finance.yahoo.com

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

July 1, 2023 | finance.yahoo.com

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

July 1, 2023 | businesswire.com

FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE

June 7, 2023 | finance.yahoo.com

Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?

June 5, 2023 | finance.yahoo.com

Monoclonal Antibodies Clinical Trial Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

June 4, 2023 | finance.yahoo.com

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Low P/S No Reason For Excitement

June 2, 2023 | finance.yahoo.com

Fate Therapeutics (FATE) Down 17.8% Since Last Earnings Report: Can It Rebound?

May 31, 2023 | finance.yahoo.com

Fate Therapeutics to Present at Upcoming June Investor Conferences

May 23, 2023 | msn.com

Fate Therapeutics: The Future Remains Cloudy

May 16, 2023 | marketwatch.com

Natural Killer Cells Therapeutics Market Analysis 2023-2030

May 8, 2023 | markets.businessinsider.com

Grabar Law Office Investigates Claims on Behalf of Shareholders of Fate Therapeutics, Inc. (FATE)

May 8, 2023 | finance.yahoo.com

Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher

See More Headlines

Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Company Calendar

Last Earnings: 8/08/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FATE
CUSIP: N/A
CIK: 1434316
Web: www.fatetherapeutics.com
Phone: (858) 875-1800
Fax: N/A
Employees: 551
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.96
High Stock Price Forecast: $65.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +494.6%
Consensus Rating: Hold
Rating Score (0-4): 2.15
Research Coverage: 20 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-281,720,000.00
Net Margins: -177.41%
Pretax Margin: -177.41%
Return on Equity: -44.14%
Return on Assets: -31.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.78
Quick Ratio: 8.78

Sales & Book Value

Annual Sales: $96.30 million
Price / Sales: 2.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.98 per share
Price / Book: 0.44

Miscellaneous

Outstanding Shares: 98,560,000
Free Float: 93,594,000
Market Cap: $214.86 million
Optionable: Optionable
Beta: 1.47

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. J. Scott Wolchko (Age 53)
Founder, CEO, Pres & Director
Comp: $645k

Mr. Edward J. Dulac III (Age 47)
Chief Financial Officer
Comp: $455k

Ms. Cindy R. Tahl (Age 50)
Gen. Counsel & Corp. Sec.
Comp: $455k

Dr. Bahram Valamehr Ph.D. (Age 46)
Chief R&D Officer
Comp: $455k

Mr. Jim Beitel M.B.A.
Sr. VP of Corp. Devel.

Dr. Jerome Bressi Ph.D.
Sr. VP of Regulatory & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FATE Stock - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings or view top-rated stocks.
What is Fate Therapeutics' stock price forecast for 2023?: 20 brokerages have issued 1 year price objectives for Fate Therapeutics' stock. Their FATE share price forecasts range from $5.00 to $65.00. On average, they predict the company's share price to reach $12.96 in the next year. This suggests a possible upside of 494.6% from the stock's current price.
View analysts price targets for FATE or view top-rated stocks among Wall Street analysts.
How have FATE shares performed in 2023?: Fate Therapeutics' stock was trading at $10.09 at the start of the year. Since then, FATE stock has decreased by 78.4% and is now trading at $2.18.
View the best growth stocks for 2023 here.
Are investors shorting Fate Therapeutics?: Fate Therapeutics saw a decrease in short interest in September. As of September 15th, there was short interest totaling 24,290,000 shares, a decrease of 12.1% from the August 31st total of 27,640,000 shares. Based on an average daily volume of 2,280,000 shares, the days-to-cover ratio is presently 10.7 days. Currently, 26.2% of the shares of the stock are sold short.
View Fate Therapeutics' Short Interest.
When is Fate Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our FATE earnings forecast.
How were Fate Therapeutics' earnings last quarter?: Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04. The biopharmaceutical company earned $0.93 million during the quarter, compared to the consensus estimate of $5.41 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 44.14% and a negative net margin of 177.41%. Fate Therapeutics's quarterly revenue was down 95.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.79) EPS.
What ETF holds Fate Therapeutics' stock ?: iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?: 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Fate Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).
What is Fate Therapeutics' stock symbol?: Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
How do I buy shares of Fate Therapeutics?: Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Fate Therapeutics' stock price today?: One share of FATE stock can currently be purchased for approximately $2.18.
How much money does Fate Therapeutics make?: Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $214.86 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.
How many employees does Fate Therapeutics have?: The company employs 551 workers across the globe.
How can I contact Fate Therapeutics?: Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.

This page (NASDAQ:FATE) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial